Celcuity initiated with a Buy at Stifel

Stifel analyst Bradley Canino initiated coverage of Celcuity with a Buy rating and $40 price target. The firm says investors “can no longer overlook” Celcuity as it moves toward pivotal data for gedatolisib due in the second half of 2024 in second-line HR+ metastatic breast cancer, stating that this cancer indication has “blockbuster potential.”